Business Wire

Movie Industry Welcomes New POWSTER Labs Team

Jaa

POWSTER, the creative studio that works with over 100 movie distributors including all six major studios, has announced a brand new division named POWSTER Labs. The team of highly skilled, creative experts based in Los Angeles will power up studios’ movie-marketing campaigns. POWSTER Labs is already aiming high, allowing moviegoers to detect the moon in their mobile web browser to activate an Augmented Reality experience for Universal Pictures’ First Man, starring Ryan Gosling. The creative marketing asset takes users on a journey to the moon while accessing behind-the-scenes footage and exclusive clips from the movie. The specialized division will pioneer developments in interactive VFX Breakdowns, interactive WebGL, 3D galleries, and interfacing with new APIs and effects released by publishers and social networks. POWSTER Labs comprises a dedicated, full-time innovation team assembled to create award-winning client campaigns, that will add new value to the entertainment industry.

POWSTER is known to redefine what is possible in digital marketing for the entertainment industry. The AR asset created by POWSTER Labs for Universal Pictures’ First Man breaks the barriers of what can be used as an AR tracker by reshaping the software’s capacity for image recognition. POWSTER is recognized for several other world firsts, including the award-winning VFX Breakdown for Pacific Rim: Uprising, which went on to win FWA Site of the Day. Audio isolation was achieved in the 360 video created for John Williams: A Life in Music, the video was honored with a Lovie Award for experimental, innovation in social media. The interactive music video engineered for “Work it Out” by Netsky has been honored as Adobe’s Cutting Edge Project of the Month. POWSTER’s creative campaign to promote the launch of Newton Faulkner’s fourth album Studio Zoo gave fans intimate access to Faulkner’s creative process via a live stream of his studio and the ability to interact with the artist on social media and control his house with Twitter. The project was named one of Google Sandbox’s Campaigns of the Year.

POWSTER Labs will continue to engineer the most innovative marketing tools available, optimized with ticket sales in mind. POWSTER CEO, Ste Thompson comments, “We are constantly pushing forward and keeping up with the way digital is changing, and I think that’s our unique quality. We aren’t just business people pushing a product, we are inventors looking at the future and constantly building new things.”

POWSTER also creates over 150 official movie destinations per month, powering ticketing websites for some of the largest blockbuster movies. Founded in London in 2009 as a sole proprietorship, Mr. Thompson sold a portion of the company to Vista Group in 2017 and expanded operations to a second studio in Los Angeles. Now, with a dedicated team housed in the same city as the major studios, there will be further innovation led by the needs of those studios. POWSTER Labs is inventing new methods of interactive storytelling; visit https://moon.firstman.com/ on your mobile browser to experience POWSTER Labs’ first mission; AR track the moon.

About POWSTER

POWSTER, part of Vista Group International (NZX & ASX: VGL), is a creative and innovation studio operating in London and Los Angeles. The business provides creative services to the film and music industry and creates products to help engage users with entertainment content. The global leader in film distribution marketing websites, POWSTER creates more than 150 destinations a month for 100+ movie distributors in over 40 countries. The POWSTER movie platform enables over five million consumers a week to discover cinema show times on official movie websites. POWSTER is modernizing how movies are marketed and delivering innovation to digital entertainment content. The future of movie marketing and interactive storytelling is coming soon.

About FIRST MAN

On the heels of their six-time Academy Award®-winning smash, La La Land, Oscar®-winning director Damien Chazelle and star Ryan Gosling reteam for Universal Pictures’ First Man , the riveting story behind the first manned mission to the moon, focusing on Neil Armstrong and the decade leading to the historic Apollo 11 flight. A visceral and intimate account told from Armstrong’s perspective, based on the book by James R. Hansen, the film explores the triumphs and the cost—on Armstrong, his family, his colleagues and the nation itself—of one of the most dangerous missions in history. www.firstman.com

First Man Creative: https://moon.firstman.com/
Website: https://labs.powster.com/
LinkedIn: www.linkedin.com/company/powster

Contact information

POWSTER
Samantha Robinson, (248) 721-2025
samantha@powster.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Arch Insurance Announces Strategic Leadership Changes19.10.2018 16:10Tiedote

Arch Insurance today announced that Matt Shulman will assume the newly created role of CEO, Arch Insurance North America, effective January 1, 2019. In this role, he will lead Arch Insurance’s operations in the United States and Canada. He will report to Nicolas Papadopoulo, Chairman and CEO of Arch Worldwide Insurance Group. Mr. Shulman, who has more than 20 years of experience in the insurance industry, has been with Arch Insurance since 2009 and has served as the President and CEO of Arch Insurance Europe since 2016. “Matt brings significant U.S. and international experience to this role. Under his leadership, together with our senior team, Arch Insurance will continue to enhance our value proposition to our customers through a robust, diversified product portfolio, creative solutions and excellent service,” Mr. Papadopoulo said. Arch Insurance has also created a new organizational structure with three Chief Underwriting Officers (CUO) dedicated to specific lines of business. These

Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer19.10.2018 15:00Tiedote

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1 st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients. Data for these secondary endpoints will be presented in a poster discussion at the European Society for Medical Oncology (ESMO) 2018 Congress on Friday, October 19 at 2:00 p.m. CET in Munich, Germany. These results further support ALUNBRIG as a potential treatment for adults with ALK+ locally advanced or metastatic NSCLC who had not received a prior ALK inhibitor. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSCLC. “ALK+ NSCLC often spreads to the brain, so having options that can clearly demonstrate efficacy both in the brain an

Vertex Receives European CHMP Positive Opinion for KALYDECO® (ivacaftor) to Treat Patients With Cystic Fibrosis Aged 12 to <24 months With Certain Mutations in the CFTR Gene19.10.2018 14:54Tiedote

Vertex Pharmaceuticals (Europe) Limited today announces that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for KALYDECO® (ivacaftor) to include the treatment of people with cystic fibrosis (CF) aged 12 to <24 months who have at least one of the following nine mutations in their cystic fibrosis transmembrane conductance regulator (CFTR) gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. If the European Commission issues a favorable adoption of the EMA CHMP opinion for the extension of indication, ivacaftor will be the first and only medicine approved in Europe to treat the underlying cause of CF in patients aged 12 to <24 months, who have specific mutations in the CFTR gene. “Cystic fibrosis is a chronic, progressive disease that is present at birth, with symptoms often occurring in infancy, so early treatment is crucial to deliver the best possible outcomes for patients,” said Reshma Kewalr

Tradeshift Announces Q3 2018 Results19.10.2018 14:00Tiedote

Tradeshift, the leader in supply chain payments and marketplaces, today announced results from the third quarter of 2018, marking the tenth quarter in a row of successive growth and beating targets. Tradeshift’s third quarter growth stats announced today include: YoY revenue grew 400 percent (trailing 12 months) YoY new bookings grew 284 percent YoY gross merchandise volume (GMV) grew 262 percent New total contract value grew by $47M in Q3 Tradeshift’s customer roster continued strong growth this quarter adding 27 new customers, including Hertz, Shiseido, ECU, and Fortune 500 leaders in retail apparel, agriculture, engineering and construction, hospitality, travel and food delivery. Tradeshift also expanded its app ecosystem by adding a key partnership with Coface, a global credit insurer. Coface has announced a new app solution on the Tradeshift platform offering risk and business information services to help businesses make decisions by ensuring greater financial transparency between

Schlumberger Announces Third-Quarter 2018 Results19.10.2018 14:00Tiedote

Schlumberger Limited (NYSE: SLB) today reported results for the third quarter of 2018. (Stated in millions, except per share amounts) Three Months Ended Change Sept. 30, 2018 Jun. 30, 2018 Sept. 30, 2017 Sequential Year-on-year Revenue $8,504 $8,303 $7,905 2% 8% Pretax operating income $1,152 $1,094 $1,059 5% 9% Pretax operating margin 13.5% 13.2% 13.4% 36 bps 15 bps Net income - GAAP basis $644 $430 $545 50% 18% Net income, excluding charges & credits* $644 $594 $581 8% 11% Diluted EPS - GAAP basis $0.46 $0.31 $0.39 48% 18% Diluted EPS, excluding charges & credits* $0.46 $0.43 $0.42 7% 10% North America revenue $3,189 $3,139 $2,602 2% 23% International revenue $5,215 $5,065 $5,147 3% 1% North America revenue, excluding Cameron $2,572 $2,546 $2,086 1% 23% International revenue, excluding Cameron $4,559 $4,387 $4,430 4% 3% *These are non-GAAP financial measures. See section below entitled "Charges & Credits" for details. Schlumberger Chairman and CEO Paal Kibsgaard commented, “Our third

Alibaba’s Robust Ecosystem Supercharges 2018 11.11 Global Shopping Festival19.10.2018 13:15Tiedote

Alibaba Group Holding Limited (NYSE:BABA) today officially kicked off the 2018 11.11 Global Shopping Festival in China’s capital, promising this year’s mega-event will be the largest-ever in terms of scale and reach. Businesses within the Alibaba ecosystem will jointly offer hundreds of millions of consumers an enriching experience that supports their pursuit of high-quality products, entertainment and fast, reliable services. The Festival will also demonstrate the enthusiasm of consumers and brands embracing Alibaba’s New Retail strategy – the convergence of online and offline retail through technology. “This year marks the 10th anniversary of 11.11. On the back of China’s explosive digital transformation, the Festival’s astounding growth over the past decade has powered the steady growth of quality consumption sought by Chinese shoppers. The evolution also showcases the development of the Alibaba ecosystem over time expanding well beyond e-commerce,” said Alibaba Group CEO Daniel Zha

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme